Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients
Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an “off-label” option in pediatric oncology. It has been previously re...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/6/330 |
| _version_ | 1797488424831156224 |
|---|---|
| author | Michal Rihacek Iveta Selingerova Ivo Kocak Ilona Kocakova Eva Rihackova Dalibor Valik Jaroslav Sterba |
| author_facet | Michal Rihacek Iveta Selingerova Ivo Kocak Ilona Kocakova Eva Rihackova Dalibor Valik Jaroslav Sterba |
| author_sort | Michal Rihacek |
| collection | DOAJ |
| description | Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an “off-label” option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, <i>p</i> = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course. |
| first_indexed | 2024-03-10T00:02:00Z |
| format | Article |
| id | doaj.art-1757570502894c7cbe87bb75a91e573a |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T00:02:00Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-1757570502894c7cbe87bb75a91e573a2023-11-23T16:14:03ZengMDPI AGCurrent Oncology1198-00521718-77292022-06-012964138414710.3390/curroncol29060330Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer PatientsMichal Rihacek0Iveta Selingerova1Ivo Kocak2Ilona Kocakova3Eva Rihackova4Dalibor Valik5Jaroslav Sterba6Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech RepublicDepartment of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech RepublicDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech RepublicDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech RepublicDepartment of Internal Cardiology Medicine, Faculty of Medicine, University Hospital Brno and Masaryk University, Jihlavska 20, 625 00 Brno, Czech RepublicDepartment of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech RepublicDepartment of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech RepublicSunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an “off-label” option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, <i>p</i> = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course.https://www.mdpi.com/1718-7729/29/6/330sunitinibmean corpuscular volumeMCVtoxicity |
| spellingShingle | Michal Rihacek Iveta Selingerova Ivo Kocak Ilona Kocakova Eva Rihackova Dalibor Valik Jaroslav Sterba Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients Current Oncology sunitinib mean corpuscular volume MCV toxicity |
| title | Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients |
| title_full | Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients |
| title_fullStr | Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients |
| title_full_unstemmed | Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients |
| title_short | Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients |
| title_sort | sunitinib induced elevation of mean corpuscular volume mcv exploring its possible clinical relevance in cancer patients |
| topic | sunitinib mean corpuscular volume MCV toxicity |
| url | https://www.mdpi.com/1718-7729/29/6/330 |
| work_keys_str_mv | AT michalrihacek sunitinibinducedelevationofmeancorpuscularvolumemcvexploringitspossibleclinicalrelevanceincancerpatients AT ivetaselingerova sunitinibinducedelevationofmeancorpuscularvolumemcvexploringitspossibleclinicalrelevanceincancerpatients AT ivokocak sunitinibinducedelevationofmeancorpuscularvolumemcvexploringitspossibleclinicalrelevanceincancerpatients AT ilonakocakova sunitinibinducedelevationofmeancorpuscularvolumemcvexploringitspossibleclinicalrelevanceincancerpatients AT evarihackova sunitinibinducedelevationofmeancorpuscularvolumemcvexploringitspossibleclinicalrelevanceincancerpatients AT daliborvalik sunitinibinducedelevationofmeancorpuscularvolumemcvexploringitspossibleclinicalrelevanceincancerpatients AT jaroslavsterba sunitinibinducedelevationofmeancorpuscularvolumemcvexploringitspossibleclinicalrelevanceincancerpatients |